PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

Qol Holdings Co., Ltd.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (14)

Qol Holdings Co., Ltd. owes ¥0.62 for every ¥1 it owns. Net profit rose 43% in the year to Mar 2026, and grew 9% a year on average over 3 years.

Compared with Healthcare companies in Japan · latest annual results Mar 2026.

P/E ratio

9.0

Investors pay ¥9.0 for every ¥1 of Qol Holdings Co., Ltd.'s yearly profit, lower than 91% of Healthcare companies in Japan.

P/B ratio

1.49

The share price is 1.49 times Qol Holdings Co., Ltd.'s book value per share, lower than 52% of Healthcare companies in Japan.

Market cap

¥85.6 B

The total market value of all of Qol Holdings Co., Ltd.'s shares at today's price (share price × number of shares), larger than 73% of Healthcare companies in Japan. PosiCap size class: Mini Cap.

Net worth (book value)

¥57.5 B

What Qol Holdings Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).

Book value per share

¥1,529

Net worth divided by the number of shares. The share price of ¥2,279 is 1.5 times this, which is the P/B above.

Return on equity (ROE)

17.2%

Qol Holdings Co., Ltd. earned 17.2% on its shareholders' money over the last year, higher than 86% of Healthcare companies in Japan.

Owes vs Owns

0.62×

Qol Holdings Co., Ltd. owes ¥0.62 for every ¥1 it owns (moderate).

Dividend yield

2.29%

Qol Holdings Co., Ltd. pays 2.29% of its share price as dividends a year, lower than 62% of dividend-paying Healthcare companies in Japan.

Revenue growth

+10%

Revenue rose 10% in the year to Mar 2026, and grew 20% a year on average over 3 years.

Profit growth

+43%

Net profit rose 43% in the year to Mar 2026, and grew 9% a year on average over 3 years.

Profit margin

2.5%

Qol Holdings Co., Ltd. keeps ¥3 of every ¥100 of revenue as net profit.

Cash quality

2.5×

Cash from Qol Holdings Co., Ltd.'s business was 2.5× its reported profit in the year to Mar 2026 — its profit turned into cash.

Interest cover

40.5×

Qol Holdings Co., Ltd.'s operating profit covered its interest costs 40.5 times in the year to Mar 2026.

Cash vs debt

Net debt

Qol Holdings Co., Ltd. had ¥16.1 B more debt than cash (net debt) at Mar 2026.

Questions

What is Qol Holdings Co., Ltd.'s P/E ratio?

Investors pay ¥9.0 for every ¥1 of Qol Holdings Co., Ltd.'s yearly profit, lower than 91% of Healthcare companies in Japan.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For Qol Holdings Co., Ltd.: ¥85.6 B ÷ ¥57.5 B (31 Mar 2026) = 1.5.

What is Qol Holdings Co., Ltd.'s return on equity?

Qol Holdings Co., Ltd. earned 17.2% on its shareholders' money over the last year, higher than 86% of Healthcare companies in Japan.

How much does Qol Holdings Co., Ltd. owe compared with what it owns?

Qol Holdings Co., Ltd. owes ¥0.62 for every ¥1 it owns (moderate).

Does Qol Holdings Co., Ltd. pay a dividend?

Yes. Qol Holdings Co., Ltd. pays 2.29% of its share price as dividends a year, lower than 62% of dividend-paying Healthcare companies in Japan.

Is Qol Holdings Co., Ltd.'s revenue growing?

Revenue rose 10% in the year to Mar 2026, and grew 20% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.